진행성 비소세포폐암에서 Vinorelbine Ifosfamide, Cisplatin (VIP) 복합항암화학요법의 효과 = Effect of Vinorelbine, Ifosfamide, and Cisplatin (VIP) combination Chemotherapy on Advanced Non-Small-Cell Lung Cancer

다국어 초록 (Multilingual Abstract)

Objectives: This study designed to evaluate the efficacy and toxicity of vinorelbine, ifosfamide, and cisplatin (VIP) combination chemotherapy in patients with advanced non-small-cell lung cancer(NSCLC), retrospectively.
Methods and Materials: From March 1997 through March 2000, ninety-one untreated patients with inoperable stage Ⅲ-Ⅳ were included. The median age was 60 years (range 37-76) : stage ⅢA/ⅢB/Ⅳ 12/34/45. The regimen consisted of vinorelbine (25㎎/㎡ day 1 and 8), ifosfamide (3,000 ㎎/㎡ day 1 with uroprotective mesna), cisplatin (60 ㎎/㎡ day 1) every 4 weeks.
Results: Ninety-one patients and total 228 cycles of chemotherapy were evaluable for toxicity and seventy-seven for response. Toxicity was mainly hematologic: grade 3-4 leukopenia (23.7%), thrombocytopenia (1.3%), and anemia(13.2%). Overall response rate was 32.5% with 25 patial responders. The median survival was 13.6 months and the mean survival 9.3±.5 months(SE). One-year survival was 54.2%. There was significant difference in survival according to the performance status (EGOG 1/2-3 8.8±.5 months/6.9±.0 months. p=0.001), which suggested that it was significant prognostic factor in this study. Responder show significant improvements in mean survival compared with non-responder (responder/non-responder 9.5±.5 months/8.3±.7 months. p=0.008).
Conclusions: The combination of vinorelbine, ifosfamide and cisplatin chemotherapy(VIP) produced acceptable efficacy and tolerance in patients with advanced NSCLC.